Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) is now available.
NeuroScientific Biopharmaceuticals Ltd announced a late lodgement of an Appendix 3Y related to the cessation of certain performance shares and options held by Director Dr. Anton Uvarov. The delay was attributed to an administrative oversight, and the company has since lodged the necessary documents with the ASX. The company reassures stakeholders of its commitment to compliance with ASX Listing Rules and plans to review its procedures to prevent future oversights, highlighting its proactive approach to governance and transparency.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Ltd is a company operating in the biopharmaceutical industry, focusing on developing treatments for neurodegenerative diseases. The company’s primary products and services are centered around innovative therapies targeting neurological conditions, aiming to improve patient outcomes in this specialized market.
Average Trading Volume: 369,324
Technical Sentiment Signal: Buy
Current Market Cap: A$7.52M
For an in-depth examination of NSB stock, go to TipRanks’ Stock Analysis page.